Free Trial
→ Crypto Gets Official Government Backing—Here's the Winner (From Crypto 101 Media) (Ad)tc pixel Free HOLX Stock Alerts

Hologic (HOLX) Stock Forecast & Price Target

Hologic logo
$64.45 -1.93 (-2.91%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$64.45 0.00 (0.00%)
As of 09/12/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Hologic - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 17 Analyst Ratings
Sell
0
Hold
8
Buy
9

Based on 17 Wall Street analysts who have issued ratings for Hologic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 8 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for HOLX.

Consensus Price Target

$78.00
21.02% Upside
According to the 17 analysts' twelve-month price targets for Hologic, the average price target is $78.00. The highest price target for HOLX is $94.00, while the lowest price target for HOLX is $68.00. The average price target represents a forecasted upside of 21.02% from the current price of $64.45.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HOLX Analyst Ratings Over Time

TypeCurrent Forecast
9/14/24 to 9/14/25		1 Month Ago
8/15/24 to 8/15/25		3 Months Ago
6/16/24 to 6/16/25		1 Year Ago
9/15/23 to 9/14/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
8 Hold rating(s)
9 Hold rating(s)
11 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$78.00$77.83$77.42$87.60
Forecasted Upside21.02% Upside14.78% Upside18.77% Upside7.95% Upside
Consensus RatingModerate BuyModerate BuyHoldModerate Buy

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Hologic Stock vs. The Competition

TypeHologicMedical CompaniesS&P 500
Consensus Rating Score
2.59
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside21.02% Upside17,489.59% Upside10.72% Upside
News Sentiment Rating
Positive News

See Recent HOLX News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/18/2025Argus
4 of 5 stars		 UpgradeHold ➝ Buy$80.00+17.98%
8/6/2025Royal Bank Of Canada
3 of 5 stars
Conor McNamara
Conor McNamara
Not Rated
UpgradeSector Perform ➝ Outperform$72.00 ➝ $87.00+28.28%
7/31/2025Mizuho
3 of 5 stars
Anthony Petrone
Anthony Petrone
Not Rated
Set Target$75.00+11.53%
7/31/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Tejas Savant
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetEqual Weight$65.00 ➝ $69.00+3.22%
7/31/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Elizabeth Garcia
Elizabeth Garcia
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetNeutral$65.00 ➝ $70.00+4.19%
7/9/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Patrick Donnelly
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeNeutral ➝ Buy$60.00 ➝ $80.00+23.27%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Vijay Kumar
Vijay Kumar
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetIn-Line$62.00 ➝ $68.00+5.64%
5/27/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
M. Matson
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingHold
5/13/2025Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Mason Carrico
Mason Carrico
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetOverweight$77.00 ➝ $70.00+22.12%
5/2/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Andrew Cooper
Andrew Cooper
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingOutperform$90.00 ➝ $71.00+33.45%
2/6/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
P. Souda
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
2/6/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingOutperform
2/6/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Puneet Souda
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$80.00 ➝ $75.00+3.02%
12/13/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
D. Schenkel
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoveragePeer Perform
12/10/2024BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
N. Ty
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong-Buy
12/10/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageHold$85.00+12.15%
11/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetOverweight$92.00 ➝ $94.00+17.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:37 PM ET.


Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Hologic, Inc.:

  • The current stock price is around $64.45, which may present a buying opportunity for investors looking for value in the medical equipment sector.
  • Hologic, Inc. has demonstrated a solid revenue growth of 1.2% year-over-year, indicating a stable demand for its products and services.
  • The company has a strong net margin of 13.79%, suggesting efficient management and profitability, which can be attractive to investors seeking reliable returns.
  • Analysts have a consensus rating of "Moderate Buy" with a target price of $78.00, indicating potential upside for investors based on market expectations.
  • Hologic, Inc. has received multiple upgrades from analysts, including a recent increase in price targets, reflecting positive sentiment about its future performance.

Hologic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Hologic, Inc. for these reasons:

  • The company reported earnings per share (EPS) of $1.06 in the previous year, which may indicate a plateau in growth compared to current expectations.
  • Despite recent upgrades, some analysts have issued "hold" ratings, suggesting caution among certain investment professionals regarding the stock's performance.
  • The stock has a relatively high P/E ratio of 26.74, which may indicate that it is overvalued compared to its earnings, potentially deterring value-focused investors.
  • Hologic, Inc. operates in a competitive market, and any shifts in healthcare regulations or market dynamics could impact its profitability and growth prospects.
  • Institutional investors currently hold 94.73% of the stock, which may limit liquidity and could lead to volatility if large shareholders decide to sell.

HOLX Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $78.00, with a high forecast of $94.00 and a low forecast of $68.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 8 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HOLX shares.

According to analysts, Hologic's stock has a predicted upside of 21.02% based on their 12-month stock forecasts.

Over the previous 90 days, Hologic's stock had 3 upgrades by analysts.

Hologic has been rated by research analysts at Argus, Citigroup, Evercore ISI, Mizuho, Morgan Stanley, Royal Bank Of Canada, and UBS Group in the past 90 days.

Analysts like Hologic less than other "medical" companies. The consensus rating score for Hologic is 2.59 while the average consensus rating score for "medical" companies is 2.78. Learn more on how HOLX compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:HOLX) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners
College grad makes $64,000 a month
A Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...
Stansberry Research | Sponsoredtc pixel
Crypto Gets Official Government Backing—Here's the Winner
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...
Crypto 101 Media | Sponsoredtc pixel
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...
Paradigm Press | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Trump’s right about Epstein.
A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....
Porter & Company | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel